YourChoice Therapeutics

YourChoice Therapeutics is focused on developing YCT-529, the first oral, hormone-free contraceptive for men, which is currently in Phase 2 clinical trials. Unlike existing male contraceptive methods, such as condoms and vasectomy, YCT-529 aims to provide a daily pill option that men can use to manage their reproductive health. The investigational agent operates by blocking the retinoic acid receptor-alpha (RAR-alpha), a receptor that plays a crucial role in sperm production, thereby offering a non-hormonal solution for male contraception. The effects on sperm production are reversible upon ce…